1. Gene Therapy Clinical Trials Worldwide . Abedia. Published 2021. Accessed August 19, 2021. http://abedia.com/wiley/.
Google Scholar2. Ginn, SL, Amaya, AK, Alexander, IE, Edelstein, M, Abedi, MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015.
Google Scholar | Crossref | Medline3. Wu, SS, Li, QC, Yin, CQ, Xue, W, Song, CQ. Advances in CRISPR/Cas-based gene therapy in human genetic diseases. Theranostics. 2020;10(10):4374–4382.
Google Scholar | Crossref | Medline4. Ramamoorth, M, Narvekar, A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01–GE06.
Google Scholar | Medline5. Liu, H, Tu, Z, Feng, F, Shi, H, Chen, K, Xu, X. Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. Acta Pharm. 2015;65(2):105–116.
Google Scholar | Crossref | Medline6. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–3142.
Google Scholar | Crossref | Medline7. Howe, SJ, Mansour, MR, Schwarzwaelder, K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143–3150.
Google Scholar | Crossref | Medline8. Li, Z, Dullmann, J, Schiedlmeier, B, et al. Murine leukemia induced by retroviral gene marking. Science. 2002;296(5567):497.
Google Scholar | Crossref | Medline9. Maetzig, T, Brugman, MH, Bartels, S, et al. Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood. 2011;117(11):3053–3064.
Google Scholar | Crossref | Medline10. Modlich, U, Kustikova, OS, Schmidt, M, et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood. 2005;105(11):4235–4246.
Google Scholar | Crossref | Medline11. Modlich, U, Schambach, A, Brugman, MH, et al. Leukemia induction after a single retroviral vector insertion in evi1 or prdm16. Leukemia. 2008;22(8):1519–1528.
Google Scholar | Crossref | Medline12. White, M, Whittaker, R, Gandara, C, Stoll, EA. A guide to approaching regulatory considerations for lentiviral-mediated gene therapies. Hum Gene Ther Methods. 2017;28(4):163–176.
Google Scholar | Crossref | Medline13. Athanasopoulos, T, Munye, MM, Yanez-Munoz, RJ. Nonintegrating gene therapy vectors. Hematol Oncol Clin North Am. 2017;31(5):753–770.
Google Scholar | Crossref | Medline14. Goswami, R, Subramanian, G, Silayeva, L, et al. Gene therapy leaves a vicious cycle. Front Oncol. 2019;9:297.
Google Scholar | Crossref | Medline15. Gonin, P, Buchholz, CJ, Pallardy, M, Mezzina, M. Gene therapy bio-safety: scientific and regulatory issues. Gene Ther. 2005;12(suppl 1):S146–S152.
Google Scholar | Crossref | Medline16. Wang, D, Tai, PWL, Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–378.
Google Scholar | Crossref | Medline17. FDA (U.S. Food and Drug Administration) . Redbook. Published 2007. Accessed August 19, 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-other-stakeholders-redbook-2000#TOC.
Google Scholar18. ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) . Tripartite guideline M3(R2), guidance on the nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Published 2009. Accessed August 19, 2021. https://database.ich.org/sites/default/files/M3_R2__Guideline.pdf.
Google Scholar19. ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) . S6, Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Published 1997. Accessed August 19, 2021. https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf.
Google Scholar20. FDA (U.S. Food and Drug Administration) . Preclinical assessment of investigational cellular and gene therapy products, guidance for industry. Published 2013. Accessed August 19, 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products.
Google Scholar21. EMA (European Medicines Agency) . Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products. Published 2008. Accessed August 19, 2021. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-studies-required-first-clinical-use-gene-therapy-medicinal-products_en.pdf.
Google Scholar22. Li, C, Samulski, RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255–272.
Google Scholar | Crossref | Medline23. Wu, Z, Asokan, A, Samulski, RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14(3):316–327.
Google Scholar | Crossref | Medline | ISI24. Naso, MF, Tomkowicz, B, Perry, WL, III, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317–334.
Google Scholar | Crossref | Medline25. Zaiss, AK, Liu, Q, Bowen, GP, Wong, NC, Bartlett, JS, Muruve, DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002;76(9):4580–4590.
Google Scholar | Crossref | Medline26. Vandamme, C, Adjali, O, Mingozzi, F. Unraveling the complex story of immune responses to AAV vectors trial after trial. Hum Gene Ther. 2017;28(11):1061–1074.
Google Scholar | Crossref | Medline27. Chandler, RJ, Sands, MS, Venditti, CP. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models. Hum Gene Ther. 2017;28(4):314–322.
Google Scholar | Crossref | Medline28. Rossi, A, Salvetti, A. Integration of AAV vectors and insertional mutagenesis. Med Sci (Paris). 2016;32(2):167–174.
Google Scholar | Crossref | Medline29. Bolt, MW, Whiteley, LO, Lynch, JL, et al. Nonclinical studies that support viral vector-delivered gene therapies: an EFPIA gene therapy working group perspective. Mol Ther Methods Clin Dev. 2020;19:89–98.
Google Scholar | Crossref | Medline30. Cavagnaro, JA . Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov. 2002;1(6):469–475.
Google Scholar | Crossref | Medline31. Colella, P, Ronzitti, G, Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87–104.
Google Scholar | Crossref | Medline32. Ma, H, Bell, KN, Loker, RN . qPCR and qRT-PCR analysis: regulatory points to consider when conducting biodistribution and vector shedding studies. Mol Ther Methods Clin Dev. 2021;20:152–168.
Google Scholar | Crossref | Medline33. FDA (U.S. Food and Drug Administration) . Human gene therapy for neurodegenerative diseases: draft guidance for industry. Published 2021. Accessed August 19, 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-neurodegenerative-diseases.
Google Scholar34. FDA (U.S. Food and Drug Administration) . Guidance for industry, long term follow-up after administration of human gene therapy products. Published 2020. Accessed August 19, 2021. https://www.fda.gov//media/113768/download.
Google Scholar35. Reuter, JD, Fang, X, Ly, CS, Suter, KK, Gibbs, D. Assessment of hazard risk associated with the intravenous use of viral vectors in rodents. Comp Med. 2012;62(5):361–370.
Google Scholar | Medline | ISI36. Nguyen, GN, Everett, JK, Kafle, S, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39(1):47–55.
Google Scholar | Crossref | Medline37. Maurer, AC, Weitzman, MD. Adeno-associated virus genome interactions important for vector production and transduction. Hum Gene Ther. 2020;31(9-10):499–511.
Google Scholar | Crossref | Medline38. Pillay, S, Zou, W, Cheng, F, et al. Adeno-associated virus (AAV) serotypes have distinctive interactions with domains of the cellular AAV receptor. J Virol. 2017;91(18):e00391–17.
Google Scholar | Crossref | Medline39. Powell, SK, Samulski, RJ, McCown, TJ. AAV capsid-promoter interactions determine CNS cell-selective gene expression in vivo. Mol Ther. 2020;28(5):1373–1380.
Google Scholar | Crossref | Medline40. Balakrishnan, B, Jayandharan, GR. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther. 2014;14(2):86–100.
Google Scholar | Crossref | Medline41. Louis Jeune, V, Joergensen, JA, Hajjar, RJ, Weber, T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24(2):59–67.
Google Scholar | Crossref | Medline42. Zincarelli, C, Soltys, S, Rengo, G, Rabinowitz, JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073–1080.
Google Scholar | Crossref | Medline43. Deverman, BE, Ravina, BM, Bankiewicz, KS, Paul, SM, Sah, DWY. Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018;17(9):641–659.
Google Scholar | Crossref | Medline44. Lotfinia, M, Abdollahpour-Alitappeh, M, Hatami, B, Zali, MR, Karimipoor, M. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies. Clin Exp Med. 2019;19(3):289–298.
Google Scholar | Crossref | Medline45. Nidetz, NF, McGee, MC, Tse, LV, et al. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacol Ther. 2020;207:107453.
Google Scholar | Crossref | Medline46. Seto, JT, Ramos, JN, Muir, L, Chamberlain, JS, Odom, GL. Gene replacement therapies for Duchenne muscular dystrophy using adeno-associated viral vectors. Curr Gene Ther. 2012;12(3):139–151.
Google Scholar | Crossref | Medline47. Reisinger, E . Dual-AAV delivery of large gene sequences to the inner ear. Hear Res. 2019;394:107857.
Google Scholar | Crossref | Medline48. McClements, ME, MacLaren, RE. Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes. Yale J Biol Med. 2017;90(4):611–623.
Google Scholar | Medline49. McCarty, DM . Self-complementary AAV vectors; advances and applications. Mol Ther. 2008;16(10):1648–1656.
Google Scholar | Crossref | Medline50. Bourdenx, M, Dutheil, N, Bezard, E, Dehay, B. Systemic gene delivery to the central nervous system using adeno-associated virus. Front Mol Neurosci. 2014;7:50.
Google Scholar | Crossref | Medline51. Miyake, K, Miyake, N, Yamazaki, Y, Shimada, T, Hirai, Y. Serotype-independent method of recombinant adeno-associated virus (AAV) vector production and purification. J Nippon Med Sch. 2012;79(6):394–402.
Google Scholar | Crossref | Medline52. Nass, SA, Mattingly, MA, Woodcock, DA, et al. Universal method for the purification of recombinant AAV vectors of differing serotypes. Mol Ther Methods Clin Dev. 2018;9:33–46.
Google Scholar | Crossref